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Adeera Levin, MD, FRCPC (Work Group Co-Chair), is
Professor of Medicine, Division Head of Nephrology at the
University of British Columbia, and Consultant Nephrologist
at Providence Health Care/St Paul’s Hospital, in Vancouver
Canada.
Dr Levin is the Executive Director of the BC Renal
Agency, which oversees the care, planning, and budgets for
kidney services in the province of British Columbia. In this
capacity, she has leveraged her epidemiological training,
clinical knowledge, and health outcomes research to develop
an evidence-based transparent system which enhances the
care of patients across the continuum of care (from
identification of CKD to dialysis, transplant, and death).
She is active in international activities across the spectrum
of kidney activities including her appointment as Secretary
General of the International Society of Nephrology (ISN),
founding executive committee member of KDIGO, and as co-
Chair of the Declaration of Istanbul Custodian group
(DICG). Dr Levin has a long-standing clinical and research
interest in CKD and CVD, and is Founding Director of the
Kidney Function Clinic at St Paul’s Hospital.
As an active researcher and mentor, she is involved in a
national curriculum development for clinician scientists
interested in kidney disease (KRESCENT), and mentors
students, residents, and nephrology fellows in Vancouver as
well. She has over 210 peer-reviewed publications, numerous
book chapters, and is co-editor of a textbook Chronic Kidney
Disease: A Practical Guide to Understanding and Management.
Her major research areas of interest include non-traditional
risk factors for CVD in CKD patients, with particular focus
on anemia, phosphate and vitamin D, and progression of
CKD variability.
Advisor/Consultant: Merck; Otsuka
Grant/Research Support: Abbott; Amgen; Canadian
Institutes of Health Research; Genzyme, Kidney Foundation
of Canada; Merck; Ortho
Paul E Stevens, MB, FRCP (Work Group Co-Chair), is
Consultant Nephrologist and Associate Medical Director,
East Kent Hospitals University NHS Foundation Trust, Kent
and Canterbury Hospital in the UK. He is a member of the
Department of Health’s Renal Advisory Group and Renal
Pathology Group and immediate past-President of the British
Renal Society. Dr Stevens established the Kent Kidney Care
Centre, one of the largest general hospital renal units in the
UK and served as a clinical advisor on NICE publications
Anaemia Management in People with Chronic Kidney Disease
and Chronic Kidney Disease: National Clinical Guideline for
Early Identification and Management in Adults in Primary and
Secondary Care. He is also Chair of NICE Quality Standards
in Chronic Kidney Disease.
His main interests include the epidemiology of CKD and
AKI, prospective evaluation of a new method of assessing
adequacy in peritoneal dialysis, evaluation of anemia in
unreferred patients with CKD and in patients with diabetes,
collaborative research with the elderly CKD care team, and
the development of information technology-based solutions
in the referral and follow-up of patients with kidney disease.
Over the last several years, his program has also developed a
clinical decision support system to aid management of
CKD in primary care and this system is currently running live
in a population of over 300,000 primary care patients.
Dr Stevens has authored over 90 publications in peer-
reviewed journals and textbooks, and has given over 100
presentations and 65 guest lectures in national and
international society meetings.
Dr Stevens reported no relevant financial relationships
Rudy W Bilous, MD, is Professor of Clinical Medicine at
Newcastle University and Honorary Consultant Physician
at the James Cook University Hospital, Middlesbrough, UK.
He studied medicine at Guy’s Hospital and completed his
clinical training at various hospitals in London. He was an
National Institutes of Health (NIH) Fellow at the Unit for
Metabolic Medicine at Guy’s from 1980-1982 working for
Professor Harry Keen and with Drs John Pickup and
Giancarlo Viberti examining the effects of metabolic control
on microvascular complications. From 1985-1987 he was
Juvenile Diabetes Research Foundation fellow at the Uni-
versity of Minnesota working for Drs Mike Steffes and Mike
Mauer. He was awarded his MD from the University of
London in 1987 and elected Fellow of the Royal College of
Physicians of London in 1991. He served as Secretary and
Chair of the Specialty Advisory Committee for Endocrinol-
ogy and Diabetes and Chairman of the Professional section of
Diabetes UK. He is currently Chairman of the workgroup
reviewing the NICE guideline for Diabetes in Pregnancy
and President of the European Diabetic Nephropathy
Study Group of the European Association for the Study of
Diabetes.
Advisor/Consultant: Abbott; Boehringer Ingelheim; Novartis;
Roche
Speaker: Boehringer Ingelheim; Novo Nordisk; Roche
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Josef Coresh, MD, PhD, MHS, is Professor, Department of
Epidemiology, Medicine, and Biostatistics at Johns Hopkins
Bloomberg School of Public Health and School of Medicine
where he also received his medical degree and PhD in
epidemiology, and a master’s in biostatistics. He is also
presently the Director of the George W Comstock Center for
Public Health Research and Prevention, and the Cardio-
vascular Epidemiology Program and Training Grant at
Johns Hopkins Bloomberg School of Public Health.
Dr Coresh’s primary research interest has been the
investigation of risk factors for CVD in CKD and their role
in mediating the excess risk among patients with various
degrees of CKD severity. With the use of innovative
epidemiologic methods and statistical analyses, his recent
work uncovered several novel genetic susceptibility loci for
gout as well as a susceptibility locus (MYH9/APOL1) which
accounts for much of the excess risk of non-diabetic kidney
disease among African-Americans. Since 2000, he has focused
his attention on enhancing CKD classification, management
and prognostication by improving the estimation of kidney
function. In 2002, he served as Co-Chair on the KDOQI
Clinical Practice Guidelines for CKD which produced the
CKD definition and classification system that have been
adopted widely today. More recently, his research led to the
development of the 2009 CKD-EPI equation for estimating
kidney function which is rapidly become the new standard
for GFR estimation globally. In 2010, he became Steering
Committee Chair of Chronic Kidney Disease Prognosis
Consortium (CKD-PC) which analyzes data from two
million study participants in order to provide better
estimation on CKD prognosis. Dr Coresh has authored close
to 300 publications and has mentored over 60 students. In
recognition of his contributions, he was awarded the NKF’s
Garabed Eknoyan Award (2010), American Heart Associa-
tion’s 2010 Epidemiology and Prevention Mentoring Award
and served as plenary speaker at the American Association
for Clinical Chemistry 2011 Annual Meeting.
Advisor/Consultant: Merck
Grant/Research Support: Amgen; National Institutes of
Health; National Kidney Foundation
Speaker: Abbott; Amgen
Angel LM de Francisco, MD, PhD, is Head of Dialysis Unit
and Nephrology Section, Hospital Universitario Valdecilla,
Santander (Spain), and Full Professor of Nephrology at
Faculty of Medicine in Cantabria University. He completed
his medical residency and nephrology fellowship at Hospital
Puerta de Hierro in Madrid, and received his Doctor of
Medicine degree from University of Cantabria (Spain). Prof
de Francisco is an active member of several professional
societies, an Executive member of the KDIGO Board, and
was President of the Spanish Society of Nephrology from
2002 to 2008. He has been a frequently invited lecturer,
speaking extensively on advancements in treatment of
chronic kidney diseases and comorbid conditions such as
metabolic bone disease, anemia, dialysis, and kidney
transplantation. Prof de Francisco has authored or coau-
thored over 150 publications, including original peer-
reviewed articles and book chapters. His primary focus has
been on improving outcomes in patients receiving hemodia-
lysis, and on issues surrounding organ transplantation and
the impact of treatment guidelines on clinical practice.
Advisor/Consultant: Amgen
Speaker: Abbott; Fresenius
Paul E de Jong, MD, PhD, was Professor of Nephrology and
Head, Division of Nephrology of the Groningen University
Medical Center in Groningen, the Netherlands from 1992
to 2011. His main research interest is prevention of CKD.
From 1980 to 2000, he focused most of his attention on the
mechanisms of urinary protein loss in CKD patients and
options to lower proteinuria with ACE-I. His studies had
indeed shown that such treatment prevented ESRD progres-
sion. In 1996, he initiated the PREVEND study which
consisted of a large cohort of 8592 subjects followed for the
development of kidney disease and CVD. This prospective
longitudinal study demonstrated the impact of albuminuria,
even in the ranges of microalbuminuria and below, in
predicting future cardiovascular and renal events. As former
Director of the Groningen Institute of Kidney Diseases, his
research program encompasses the studying of underlying
susceptibility to kidney damage in health subjects and the
identification of common pathophysiological pathways
between CKD and CVD. Currently, he serves on the board
of KDIGO, CKD-PC, and European Kidney Health Alliance.
In 2010, he was the recipient of International Distinguished
Medal from the US National Kidney Foundation and was
awarded the Officer in the Order of Orange-Nassau for his
lifetime achievement by Her Majesty Queen Beatrix of the
Netherlands in 2011.
Dr de Jong reported no relevant financial relationships
Kathryn E Griffith, BM, BS, MSc, MRCP, MRCGP, is a
general practitioner affiliated with The University Health
Centre, York University and York Hospital Foundation Trust.
Dr Griffith has a long-standing interest in the relationship
between CVD and renal disease from a primary care
physician’s perspective. In this vein, she has served as a panel
member for the Royal College of Physicians (RCP)
Edinburgh Consensus Conference on CKD and was involved
in the development of the 18-week Commissioning Pathway
to CKD with the Department of Health. She is presently a
member of the Renal Advisory Group at the Department of
Health and a member of both UK Renal Association and
British Renal Society. Dr Griffith has also been involved in
the education of general practitioners and practice nurses,
and most recently she has lectured extensively on various
topics such as atrial fibrillation, heart failure, coronary heart
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disease, hypertension, and stroke. For the past two years, she
has worked with Yorkshire Cardiac and Stroke Networks
on a guide to stroke prevention in atrial fibrillation, and
contributed to the RCP Edinburgh Consensus on atrial
fibrillation management and European Society of Cardio-
logy’s clinical practice guideline on management of
dyslipidemias.
Advisor/Consultant: Boehringer Ingelheim
Honoraria: Pfizer
Travel Stipend: Merck Sharp & Dohme
Grant/Research Support: Roche
Speaker: Boehringer Ingelheim
Brenda R Hemmelgarn, MD, PhD, FRCP(C), is Associate
Professor in the Departments of Medicine and Community
Health Sciences, University of Calgary, Calgary, Alberta. She
is a clinician scientist with clinical training in nephrology
as well as a PhD in Epidemiology and Biostatistics.
Dr Hemmelgarn’s research interests are in the study of
chronic medical conditions including CKD, diabetes, hyper-
tension and CVD, as well as health services research aimed
at improving management of these chronic conditions.
Dr Hemmelgarn holds provincial and national salary awards
and operating grants, and is the recipient of the Roy and
Vi Baay Chair in Kidney Research. She is also actively
involved in Clinical Practice Guideline development both
nationally through the Canadian Society of Nephrology
and internationally through KDIGO, and has over 180
peer-reviewed publications.
Grant/Research Support: Roche
Kunitoshi Iseki, MD, is currently affiliated with
University Hospital of the Ryukyus in Okinawa, Japan.
Dr Iseki received his medical training at Kyushu University
in Fukuoka, Japan and completed his fellowship at University
of Southern California under Professors Shaul Massry
and Vito Campese. He was Senior Assistant Professor of
Medicine at Ryukyu University Hospital and later became
its Director of Dialysis Unit. Dr Iseki is a member of
numerous professional organizations including the Japanese
Society of Nephrology and Japanese Society for Dialysis
Therapy. He is also an organizing member for Asian Forum
of Chronic Kidney Disease Initiatives (AFCKDI) since 2007
and an ISN-COMGAN Educational Ambassador since
2009. Dr. Iseki has also participated and contributed data
to the CKD-PC whose collaborative meta-analyses were
conducted to study CKD prognosis. He has previously served
as Editorial board member for American Journal Kidney
Disease and is presently an editorial board member of
Nephrology, Nephron Clinical Practice and Nephrology Dialysis
Transplantation.
Dr Iseki reported no relevant financial relationships
Edmund J Lamb, PhD, FRCPath, is a Consultant Clinical
Scientist and Head of Clinical Biochemistry at East Kent
Hospitals University NHS Foundation Trust, Canterbury,
Kent, UK. He has a special interest in kidney disease and
undertook his PhD in the Renal Research Laboratory at
St Bartholomew’s Hospital, London. He has 30 years
experience as a clinical biochemist and his research
interests relate to the use of biochemical markers to diag-
nose and monitor kidney disease, including the assess-
ment of kidney function using eGFR, the evaluation of
renal bone disease, the use and role of cystatin C, and the
significance and use of cardiac biomarkers in kidney
disease. Dr Lamb has authored or co-authored more than
60 full peer-reviewed papers in this area. He is a member
of the UK Kidney Research Consortium Clinical Study
Group on CKD-MBD and he is the lead investigator on two
National Institute for Health Research-Research for Patient
Benefit funded studies investigating aspects of kidney
function testing. He has been involved in national and
international committees and guidelines (e.g., Royal College
of Physicians UK CKD Guidelines Group, NICE CKD
Guideline Development Group, KDIGO Chronic Kidney
Disease Guideline Work Group) and was recently involved
in the Department of Health initiative to roll-out eGFR
across England. He is Editor-in-Chief of Annals of Clinical
Biochemistry.
Grant/Research Support: Siemens
Andrew S Levey, MD, is Dr Gerald J and Dorothy
R Friedman Professor of Medicine at Tufts University School
of Medicine, Chief of the William B Schwartz, MD Division
of Nephrology at Tufts Medical Center, Senior Scientist at the
US Department of Agriculture Human Nutrition Research
Center on Aging at Tufts University, and Professor, Clinical
Research at the Sackler School of Graduate Biomedical
Sciences at Tufts University. His research is mainly in the
areas of epidemiology of CKD and CVD in CKD, controlled
trials to slow the progression of CKD, clinical assessment of
kidney function, assessment and improvement of outcomes
in dialysis and transplantation, and clinical practice guideline
development and implementation. Dr Levey is currently
Program Director for an NIDDK-funded clinical research
training program, ‘‘Clinical Trials, Epidemiology and Out-
comes Research in Nephrology.’’ He is also the Director of the
Tufts Center for Guideline Development and Implementation
and Editor of American Journal of Kidney Disease. Dr Levey
is past Chair of the NKF’s Task Force on Cardiovascular
Disease in Chronic Renal Disease and served on KDOQI
Work Group on Chronic Kidney Disease: Evaluation,
Classification and Stratification, KDOQI Work Group on
Hypertension and Antihypertensive Agents in Chronic
Kidney Disease, and KDIGO Work Group on Acute Kidney
Injury Guideline.
Dr Levey reported no relevant financial relationships
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Miguel C Riella, MD, PhD, FACP, is a graduate of Federal
University of Parana in Curitiba, Brazil and has undertaken
his post-graduate training in the United States, first in
Internal Medicine Residency at Mount Sinai Hospital in
New York City and then Research Renal Fellowship at the
University of Washington in Seattle, USA under the leader-
ship of Prof Belding H Scribner, pioneer of chronic
hemodialysis. Dr Riella’s main interest has been on dialysis,
particularly peritoneal dialysis and nutrition in uremia. More
recently his research work has concentrated on the relation-
ship of inflammation, uremia, nutrition and cardiovascular
complications, and interventional nephrology. As part of
his new Renal, Diabetes and Hypertension Research Center,
he has recently established the Islet Cell Laboratory at Catholic
University of Parana in Curitiba, Brazil for cell transplant in
diabetic patients. Dr Riella has published several books in
Portuguese and Spanish language in the area of nephrology
and nutrition. His book Principles of Nephrology and Electrolyte
Disturbances (Guanabara Koogan Group Gen, 2010) is on its
5th Edition. He has more than 150 publications and has given
more than 600 lectures locally and internationally. He is a past
Board member and executive committee member of the ISN
and is currently the Chairman of the ISN-Interventional
Nephrology Committee. Dr Riella is a member of the editorial
board of several medical journals, including as Associate Editor
of Hemodialysis International and International Editor of
Seminar in Dialysis for Interventional Nephrology. He is also
President and founder of Pro-Renal Foundation of Brazil
(www.pro-renal.org.br), a non-for-profit organization dedi-
cated to patient assistance, CKD prevention and education,
and supporting research in kidney and metabolic diseases. The
Foundation provides free medical care to more than 1800 renal
patients through a multidisciplinary team of physicians, nurses,
psychologists, social workers, and dietitians. The Foundation is
maintained by donations of the community and receives no
public funds. Dr Riella is the past-President of the Interna-
tional Federation of Kidney Foundations (IFKF) 2009-2011.
He is also the co-chairman of World Kidney Day, a joint
project of IFKF and and ISN. He is a member of the Executive
Committee of KDIGO, National Academy of Medicine in
Brazil, and the Academy of Medicine of Parana, Brazil. He has
received many awards such as the International Distinguished
Medal from the US NKF and Honorary Citizenship of the city
of Curitiba and of the State of Parana in Brazil.
Advisor/Consultant: Abbott
Michael G Shlipak, MD, MPH, is Professor of Medicine,
Epidemiology, and Biostatistics at University of California,
San Francisco. Dr Shlipak obtained his MD degree from
Harvard Medical School and his MPH from Harvard School
of Public Health. His research program has been dedicated to
understanding the causes and consequences of age-related
kidney disease and to utilize novel biomarkers for the early
detection of kidney damage and reduced kidney function.
Along with his colleagues from the Cardiovascular Health
Study and Health Aging and Body Composition study,
Professor Shlipak has conducted the pioneering work to
demonstrate with cystatin C the remarkable prognostic
importance of impaired kidney function in elders. He coined
the entity of ‘‘preclinical kidney disease’’ to describe the large
population of elders with elevated cystatin C levels, but
normal creatinine-based estimates of kidney function, who
are at high risk for death and CVD.
The recent work from his research group has been
dedicated to finding early markers of kidney injury in the
urine that will precede any detectable loss in kidney function.
They will study these urine biomarkers in several popula-
tions, including the ambulatory elderly, HIV-infected men
and women, and in population-based studies. The group
believes that these injury markers hold promise both for
understanding how various exposures impact the kidney, and
also to forecast future declines in kidney failure.
Dr Shlipak reported no relevant financial relationships
Haiyan Wang, MD, is Professor of Medicine at Peking
University First Hospital. She is the current President of
Peking University Institute of Nephrology and the Vice
Director, Academic Committee, Peking University Health
Science Center and Member, Academic Degree Committee,
Peking University Health Science Center.
Professor Wang is very active in the academic area of
national and international nephrology and internal medicine.
She was the Vice President of Chinese Medical Association
(1999-2009) and the President of Chinese Society of Internal
Medicine (2000-2008), as well as the President of Chinese
Society of Nephrology (1992-1998). She has also served
as the ISN Councilor member (2004-2008), Executive
Councilor of ISN (2006-2008) and is now Chair, East Asia
committee of ISN GO (2004-present).
Dr Wang reported no relevant financial relationships
Colin T White, MD, FRCPC, completed his medical degree at
the University of Ottawa, Canada and Pediatric Residency at
the University of Western Ontario, Canada. His pediatric
nephrology training took place at the University of Western
Ontario and University of British Columbia. He is a Clinical
Associate Professor in Pediatrics/Nephrology at the University
of British Columbia and has a clinical appointment at BC
Children’s Hospital where in addition to an interest and partici-
pation in the CKD clinic, he is the Director of the Dialysis
Program and is the Fellowship Program Director. Dr White was
a work group member for the 2006 and 2007 Updated KDOQI
Anemia Guidelines, and for the Canadian Society of Nephro-
logy’s Clinical Practice Guidelines for Anemia Management in
2007-2008; he is currently on the 2011-2012 CSN Workgroup
revisiting these guidelines. He is the site Principal Investigator
for the North American multicenter NIH-sponsored CKiDs
trial and has particular research interests in hemodialysis and
peritoneal dialysis as well as CKD management. His particular
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areas of research interest include estimation of clearance,
anemia protocol development, and translation of evidence
into functional guidelines. He is active at the undergraduate
medical school level and has coordinated the UBC Renal and
Genitourinary Course for 1st year medical students for nearly a
decade. He is currently the President of the Western Society of
Pediatric Research and an invited member of the Renal Work
Group for the World Health Organization’s ICD-11 Code
Revision.
Advisor/Consultant: Baxter Healthcare
Christopher G Winearls, MB, DPhil, FRCP, graduated in
1973 from University of Cape Town and as a Rhodes Scholar
completed a PhD from University of Oxford in transplant
immunology. Dr Winearls later pursued training in nephro-
logy at the Hammersmith Hospital where he was part of the
team that investigated the first clinical use of erythropoietin.
Dr Winearls was appointed consultant in Oxford in 1988 and
was Clinical Director 1995 to 2009. He has been Secretary
and later Clinical Vice President of The Renal Association
and an Editor of the Oxford Textbook of Clinical Nephrology.
His research interests include myeloma kidney and auto-
somal dominant polycystic kidney disease, and has recently
taken an interest in the new classification of CKD.
Dr Winearls reported no relevant financial relationships
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Bertram L Kasiske, MD, is Professor of Medicine at the
University of Minnesota, USA. He received his medical
degree from the University of Iowa and completed his
Internal Medicine residency and fellowship training in
Nephrology at Hennepin County Medical Center where he
is currently Director of Nephrology.
Dr Kasiske is former Deputy Director of the United States
Renal Data System and former Editor-in-Chief of American
Journal of Kidney Diseases. He has served as Secretary/
Treasurer and on the Board of Directors of the American
Society of Transplantation, and on the Organ Procurement
and Transplantation Network/United Network of Organ
Sharing Board of Directors, and the Scientific Advisory
Board of the US NKF. He is currently serving on the Board of
Councilors of the ISN and he is the Principal Investigator for
a National Institutes of Health-sponsored, multicenter study
of long term outcomes after kidney donation. Dr Kasiske is
the Director of the Scientific Registry of Transplant
Recipients and has over 160 scientific publications in major
peer-reviewed journals, and 230 review articles, editorials and
textbook chapters. Dr Kasiske is also a recipient of the US
NKF’s Garabed Eknoyan Award in 2003.
Advisor/Consultant: Litholink
Grant/Research Support: Bristol-Myers Squibb; Merck
(Schering Plough)
David C Wheeler, MD, FRCP, holds an academic position in
Nephrology (Reader) at University College London, UK and
is an Honorary Consultant Nephrologist at the Royal Free
Hospital. His research is focused on the cardiovascular
complications of CKD and the role of vascular risk factors in
progression of kidney damage. Dr Wheeler is a member of
the International Steering Committee of the Study of
Heart and Renal Protection (SHARP) and was UK National
Coordinator for the trial. He is involved in several other
randomized trials and observational studies involving
patients with CKD.
Dr Wheeler is Co-Chair of KDIGO, having served
previously on its Executive Committee and Board. He
received an International Distinguished Medal from the
US NKF in recognition of his contribution to guideline
development. In the UK, he has been elected President of
the Renal Association for the term 2012-2014.
Dr Wheeler has served on the editorial boards of American
Journal of Kidney Diseases and Journal of the American Society
of Nephrology and is presently Co-Editor for Nephrology
Dialysis Transplantation.
Advisor/Consultant: Amgen
Honoraria: Abbott; Amgen; Fresenius; Otsuka; Shire
Travel Stipend: Amgen; Merck Sharp & Dohme; Shire
Grant/Research Support: Abbott; Genzyme
EVIDENCE REVIEW TEAM
Katrin Uhlig, MD, MS, is the Director, Guideline Develop-
ment at the Tufts Center for Kidney Disease Guideline
Development and Implementation, Boston, MA, USA,
Associate Professor of Medicine at Tufts University School
of Medicine, and a staff nephrologist at Tufts Medical Center.
Dr Uhlig completed her training in internal medicine,
nephrology, and rheumatology in Germany (Aachen Uni-
versity Hospital and Munich University Hospital) and the
USA (Georgetown University Medical Center and Tufts
Medical Center). Since 2001, she has been participating in or
directing the evidence review for KDOQI and KDIGO
guidelines. As Director of Guideline Development, Dr Uhlig
has a substantial role in coordinating the ERT. She
orchestrates and supervises the guideline development
process and didactic curriculum that provides Work Group
members with formal instruction on topics related to guide-
line development. As project director on individual guide-
lines, she directs and supervises the collection, evaluation,
grading, and synthesis of evidence and the drafting and
revisions of the final evidence report. She provides metho-
dological guidance and training to Work Group members at
meetings regarding topic refinement, key question formula-
tion, data extraction, study assessment, evidence grading,
and recommendation formulation. She provides nephrology
expertise in the interpretation and review of guide-
line recommendations and evidence reports. In this capacity,
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Dr Uhlig possesses unique knowledge as a methods expert in
evidence synthesis and critical literature appraisal in the
domain of nephrology.
In 2005, she co-chaired the KDIGO Evidence Rating
Group to develop a consensus on grading of KDIGO
guidelines and also co-chaired the KDIGO Consensus
Conference on Guideline Methodology in October
2007. From 2006 to 2007, she served as Co-Editor of
American Journal of Kidney Diseases. Her teaching and
research focus includes evidence-based medicine, systematic
review, clinical practice guideline development, and critical
literature appraisal. Dr Uhlig lectures on guideline topics and
is a co-instructor of an annual course on meta-analysis in the
Master of Science Program at the Sackler School of Graduate
Biomedical Sciences at Tufts University.
Dr Uhlig reported no relevant financial relationships
Dana C Miskulin, MD, MS, is Assistant Professor of
Medicine at Tufts University School of Medicine, Boston,
MA, USA. She completed a fellowship in Clinical Care
Research and participated in the conduct of systematic
reviews and critical literature appraisals for this guideline.
Her primary research interests are in comparative effective-
ness research in dialysis patients, BP treatment in dialysis
patients, and autosomal dominant polycystic kidney disease.
Dr Miskulin reported no relevant financial relationships
Amy Earley, BS, is a project coordinator at the Tufts Center
for Kidney Disease Guideline Development and Implementa-
tion in Boston, MA, USA. She is key in coordinating the
guideline development activities within the ERT, especially in
the development of the evidence reports for all guidelines.
Ms Earley also heads the actual evidence review, which
includes running searches, screening, data extraction,
drafting of tables and methods sections, proofing of guideline
drafts, and critical literature appraisals. She participates in
the conduct of research projects at the Center and actively
collaborates with other members of the Center on indepen-
dent research topics and manuscript submissions.
Ms. Earley reported no relevant financial relationships
Shana Haynes, MS, DHSc, is a research assistant at the Tufts
Center for Kidney Disease Guideline Development and
Implementation in Boston, MA, USA. She participates in
all aspects of evidence review and guideline development. She
screens abstracts and articles, extracts data, and assists in the
drafting and editing of evidence tables. Dr Haynes also assists
in the development of clinical practice guidelines and
conducts systematic reviews and critical literature appraisals.
Dr Haynes reported no relevant financial relationships
Jenny Lamont, MS, is a project manager and medical writer
at the Tufts Center for Kidney Disease Guideline Develop-
ment and Implementation in Boston, MA, USA. She
participates in all aspects of evidence review and guideline
development, assists in the preparation of talks and manu-
scripts, and edits KDIGO draft guidelines currently in
progress.
Ms. Lamont reported no relevant financial relationships
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